MagicMed Industries Inc. is a biotechnology company founded in 2020. The company is focused on creating a library of novel derivative molecules based on classic psychedelics such as psilocybin, N,N-dimethyltryptamine (DMT), mescaline, ibogaine, MDMA and LSD. MagicMed’s molecular derivatives library, the Psybrary™, is intended to be an essential building block from which industry partners can develop new patented products.
MagicMed’s mission is to unlock the full potential of psychedelic-derived medicines for the treatment of neurological and psychological indications.
MagicMed is focused on the discovery and early development of novel drug candidates, structurally related to the classic psychedelics but with vastly improved pharmaceutical characteristics and commercial potential.
There has been a resurgence of interest in psychedelics as researchers look to create alternative treatment solutions for a growing patient base.
Early clinical results, increased corporate and media support and a regulatory thaw of these Schedule I compounds have created the perfect framework for the industry to benefit from what psychedelics have to offer.
In the last few years, classic psychedelics have shown the potential to provide an improved, alternative treatment solution to a vast array of mental health indications – ranging from treatment-resistant depression and anxiety to PTSD.